After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Incyte Corporation (INCY) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $72.86. The Incyte Corporation has recorded 55,737 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte’s Oncology Pipeline.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
INCY belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $72.86 and fluctuated between $74.21 as its day high and $72.46 as its day low. The current market capitalization of Incyte Corporation is $16.19B. A total of 0.96 million shares were traded on the day, compared to an average of 1.62M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, INCY has seen 27 BUY and 24 SELL insider trades, representing the acquisition of 167,234 and the disposition of 118,516 shares. Over the last 12 months, there were 70 BUYs and 42 SELLs from insiders. Insiders purchased 611,084 shares during that period but sold 225,807.
In the most recent transaction, Pasquale Maria E sold 802 shares of INCY for 84.06 per share on Jan 31. After the transaction, the EVP & General Counsel now owns 68,524 company shares. In a previous transaction on Jan 30, Pasquale Maria E sold 60,024 shares at 84.74 per share. INCY shares that EVP & General Counsel owns now total 68,524.
Among the insiders who sold shares, Iyengar Vijay K disposed of 7,000 shares on Jan 26 at a per-share price of $85.00. This resulted in the EVP, GMAPPS holding 42,835 shares of INCY after the transaction. In another insider transaction, Dhanak Dashyant sold 2,419 shares at $85.00 per share on Jan 26. Company shares held by the EVP & Chief Scientific Officer now total 53,263.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for INCY in the last 3 months, the mean price target is $89.56 with high estimates of $118.00 and low estimates of $63.00. In terms of 52-week highs and lows, INCY has a high of $86.29 and a low of $65.07.
As of this writing, INCY has an earnings estimate of $0.69 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $0.9 per share and a lower estimate of $0.46. The company reported an EPS of $0.6 in the last quarter, which was -16.70% lower than expectations of $0.72.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 21 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for INCY is Sell with a score of 3.73. A total of 10 analysts rated the stock as Buy while 1 rated it as Overweight while 9 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.